Nicole Faust, Ph.D., CEO

April 21 | 1:30pm | Gaudi 2 Ballroom

Cologne, Germany


In-Person Presentation

CEVEC is a leading provider of high-performance cell technology for the manufacturing of advanced biotherapeutics from R&D to manufacturing scale. The company’s product portfolio comprises platform technologies for gene therapy viral vectors (AAV, adenoviral vectors, lentiviral vectors) vaccines and complex recombinant proteins. With the ELEVECTA® Technology, CEVEC offers a unique solution for large-scale, transfection- and helper virus-free production of AAV vectors using producer cell lines with all necessary components stably integrated into the cell. The technology is based on suspension cells and does not require any transfection reagents, cGMP plasmids, or helper virus.


By using this website you agree to accept our Privacy Policy and Terms & Conditions